Skip to main content
ADVANCED SEARCH
Log in
Top
Current Oncology Reports

26-04-2025 | Xanthine Alkaloid | REVIEW

Linking Hyperuricemia to Cancer: Emerging Evidence on Risk and Progression

Authors: Lingyun Zhao, Ruihong Guo, Ziming Zhao, Jue Wang, Zhonghan Lou, Jianfeng Bao, Wei Zheng, Qiang Wang, Liang Qiao, Yun Ye, Hiu Yee Kwan, Hua Zhou, Qibiao Wu, Keyang Xu

Published in: Current Oncology Reports

Login to get access

Abstract

Purpose of Review

Metabolic disorders significantly contribute to cancer burden globally. Uric acid (UA), a recognized metabolic risk factor linked to gout, also promotes insulin resistance, fatty liver, inflammation, and carcinogenesis. This systematic review evaluates UA’s dual role in cancer, synthesizing epidemiological, mechanistic, and clinical evidence to clarify its potential as a therapeutic target.

Recent Findings

The research of UA on cancer development mainly focuses on a clinical observational study, with limited molecular mechanism exploration. The associations between UA and cancer risk remain controversial, as sometimes the antioxidant, anti-inflammatory and immune-enhancing properties of UA are presented. There is lacking a systematic and updated review for summarizing the role of hyperuricemia on cancer risk and progression. The precise mechanism of UA in either enhancing or inhibiting cancer progression remains uncertain.

Summary

Serum uric acid (SUA) exhibits paradoxical roles in cancer, with its effects varying by tumor type, concentration, gender, and disease stage. While UA predominantly drives tumorigenesis in most cancers, it shows protective effects in specific malignancies such as soft-tissue sarcoma and laryngeal squamous cell carcinoma, potentially through antioxidant activity at lower concentrations. Mechanistically, UA highly participate in the cancer risk and progression through reactive oxygen species (ROS) generation, disrupting T cell activation and dendritic cell maturation, exacerbating insulin resistance, and driving xanthine oxidoreductase (XOR) expression during the process of wound healing. Emerging clinical and mechanistic evidence highlights its oncogenic potential, underscoring the need for large-scale randomized controlled trials and cohort studies to clarify the relationship between hyperuricemia and cancer progression. Future research should prioritize exploring anti-UA therapies for cancer treatment, developing advanced animal models to dissect UA’s mechanisms, and integrating diverse genomic datasets to unravel its context-dependent roles. Addressing these gaps will advance targeted strategies to leverage UA biology in cancer management.
Literature
1.
2.
3.
4.
Yang J, et al. The predictive value of TyG and lipid ratios on the development of complications and hyperuricemia in patients with type 2 diabetes mellitus. Lipids. 2024;59(6):209–19.PubMedCrossRef
5.
6.
Dovell F, Boffetta P. Serum uric acid and cancer mortality and incidence: a systematic review and meta-analysis. Eur J Cancer Prev. 2018;27(4):399–405.PubMedCrossRef
7.
Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab. 2020;319(5):E827-e834.PubMedCrossRef
8.
9.
Kim MJ, Mayr M. Uric acid and kidneys – Physiological and pathophysiological aspects. Therapeutische Umschau. Revue Ther. 2016;73(3):167–75.
10.
11.
12.
Song D, et al. A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications. Eur J Pharmacol. 2021;907:174291.PubMedCrossRef
13.
14.
Yiu A, et al. Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study. Oncotarget. 2017;8(26):42332–42.PubMedPubMedCentralCrossRef
15.
Horsfall LJ, Nazareth I, Petersen I. Serum uric acid and the risk of respiratory disease: a population-based cohort study. Thorax. 2014;69(11):1021–6.PubMedCrossRef
16.
Strasak AM, et al. Use of penalized splines in extended Cox-type additive hazard regression to flexibly estimate the effect of time-varying serum uric acid on risk of cancer incidence: a prospective, population-based study in 78,850 men. Ann Epidemiol. 2009;19(1):15–24.PubMedCrossRef
17.
Benli E, et al. Comparison of serum uric acid levels between prostate cancer patients and a control group. Cent European J Urol. 2018;71(2):242–7.PubMedPubMedCentral
18.
Deng Z, et al. Association between uric acid, cancer incidence and mortality in patients with type 2 diabetes: Shanghai diabetes registry study. Diabetes Metab Res Rev. 2016;32(3):325–32.PubMedCrossRef
19.
Yang J, et al. Association of serum uric acid with increased risk of cancer among hypertensive Chinese. Int J Cancer. 2017;141(1):112–20.PubMedCrossRef
20.
Wang A, et al. Serum urate, genetic variation, and prostate cancer risk: Atherosclerosis risk in communities (ARIC) study. Cancer Epidemiol Biomarkers Prev. 2019;28(7):1259–61.PubMedPubMedCentralCrossRef
21.
Lawal AO, Kolude B, Adeyemi BF. Serum uric Acid levels in oral cancer patients seen at tertiary institution in Nigeria. Ann Ib Postgrad Med. 2012;10(1):9–12.PubMedPubMedCentral
22.
Hiatt RA, Fireman BH. Serum uric acid unrelated to cancer incidence in humans. Cancer Res. 1988;48(10):2916–8.PubMed
23.
Kobylecki CJ, Afzal S, Nordestgaard BG. Plasma urate, cancer incidence, and all-cause mortality: A Mendelian randomization study. Clin Chem. 2017;63(6):1151–60.PubMedCrossRef
24.
Kolonel LN, et al. Relationship of serum uric acid to cancer occurrence in a prospective male cohort. Cancer Epidemiol Biomarkers Prev. 1994;3(3):225–8.PubMed
25.
26.
Chen CJ, et al. Allopurinol and the incidence of bladder cancer: a Taiwan national retrospective cohort study. Eur J Cancer Prev. 2016;25(3):216–23.PubMedCrossRef
27.
Kuo CF, et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford). 2013;52(1):127–34.PubMedCrossRef
28.
29.
Mi N, et al. High serum uric acid may associate with the increased risk of colorectal cancer in females: A prospective cohort study. Int J Cancer. 2022;150(2):263–72.PubMedCrossRef
30.
Huang CF, et al. Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study. World J Gastroenterol. 2020;26(44):7061–75.PubMedPubMedCentralCrossRef
31.
32.
Deng Y, Huang J, Wong MCS. Association between serum uric acid and prostate cancer risk in East Asian populations: a Mendelian randomization study. Eur J Nutr. 2023;62(3):1323–9.PubMedCrossRef
33.
Fan K, Sun T, Yin F. J-shaped association between uric acid and breast cancer risk: a prospective case-control study. J Cancer Res Clin Oncol. 2023;149(10):7629–36.PubMedPubMedCentralCrossRef
34.
Feng Y, et al. Uric acid mediated the association between BMI and postmenopausal breast cancer incidence: A bidirectional mendelian randomization analysis and prospective cohort study. Front Endocrinol (Lausanne). 2021;12:742411.PubMedCrossRef
35.
Lin P, et al. Exploring the causal association between uric acid and lung cancer in east Asian and European populations: a mendelian randomization study. BMC Cancer. 2024;24(1):801.PubMedPubMedCentralCrossRef
36.
Kim YR, et al. Association between Albumin, Total Bilirubin, and Uric Acid Serum Levels and the Risk of Cancer: A Prospective Study in a Korean Population. Yonsei Med J. 2021;62(9):792–8.PubMedPubMedCentralCrossRef
37.
Yan S, et al. Serum Uric Acid Increases Risk of Cancer Incidence and Mortality: A Systematic Review and Meta-Analysis. Mediators Inflamm. 2015;2015:764250.PubMedPubMedCentralCrossRef
38.
Szkandera J, et al. Uric acid levels in blood are associated with clinical outcome in soft-tissue sarcoma patients. Clin Chem Lab Med. 2015;53(3):493–7.PubMedCrossRef
39.
40.
Strasak AM, et al. Serum uric acid and risk of cancer mortality in a large prospective male cohort. Cancer Causes Control. 2007;18(9):1021–9.PubMedCrossRef
41.
Taghizadeh N, Vonk JM, Boezen HM. Serum uric acid levels and cancer mortality risk among males in a large general population-based cohort study. Cancer Causes Control. 2014;25(8):1075–80.PubMedPubMedCentralCrossRef
42.
Strasak AM, et al. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28 000 older Austrian women. Ann Oncol. 2007;18(11):1893–7.PubMedCrossRef
43.
Gapstur SM, et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000;283(19):2552–8.PubMedCrossRef
44.
Jee SH, Lee SY, Kim MT. Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men. Eur J Cardiovasc Prevent Rehab. 2004;11(3):185–91.CrossRef
45.
Juraschek SP, Tunstall-Pedoe H, Woodward M. Serum uric acid and the risk of mortality during 23 years follow-up in the Scottish Heart Health Extended Cohort Study. Atherosclerosis. 2014;233(2):623–9.PubMedPubMedCentralCrossRef
46.
Levine W, et al. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol. 1989;42(3):257–67.PubMedCrossRef
47.
Tomita M, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol. 2000;10(6):403–9.PubMedCrossRef
48.
Wu CY, et al. High serum uric acid levels are associated with all-cause and cardiovascular, but not cancer, mortality in elderly adults. J Am Geriatr Soc. 2015;63(9):1829–36.PubMedCrossRef
49.
Mazza A, et al. Predictors of cancer mortality in elderly subjects. Eur J Epidemiol. 1999;15(5):421–7.PubMedCrossRef
50.
Yue CF, et al. High serum uric acid concentration predicts poor survival in patients with breast cancer. Clin Chim Acta. 2017;473:160–5.PubMedCrossRef
51.
Li S, et al. Repeated measurements of serum urate and mortality: a prospective cohort study of 152,358 individuals over 8 years of follow-up. Arthritis Res Ther. 2020;22(1):84.PubMedPubMedCentralCrossRef
52.
Yim K, et al. Rising serum uric acid level is negatively associated with survival in renal cell carcinoma. Cancers (Basel). 2019;11(4):536.PubMedCrossRef
53.
Penack O, et al. Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working Party. Haematologica. 2020;105(7):1977–83.PubMedPubMedCentralCrossRef
54.
Chang DY, et al. Association between serum uric acid level and mortality in China. Chin Med J (Engl). 2021;134(17):2073–80.PubMedCrossRef
55.
Hu L, et al. U-shaped association of serum uric acid with all-cause and cause-specific mortality in us adults: A cohort study. J Clin Endocrinol Metab. 2020;105(1):e597–609.CrossRef
56.
Lee YHA, et al. Association between serum uric acid and prostate cancer mortality in androgen deprivation therapy: A population-based cohort study. Cancer Med. 2023;12(16):17056–60.PubMedPubMedCentralCrossRef
57.
Fernandez ML, et al. Elevated uric acid correlates with wound severity. Int Wound J. 2012;9(2):139–49.PubMedCrossRef
58.
59.
Tanriverdi O, et al. Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish descriptive oncological researches group. Med Oncol. 2014;31(10):217.PubMedCrossRef
60.
Chen YF, et al. Prognostic value of pre-operative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy. Cancer Biomark. 2016;17(1):89–96.PubMedCrossRef
61.
Lin H, et al. Plasma uric acid and tumor volume are highly predictive of outcome in nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy. Radiat Oncol. 2013;8:121.PubMedPubMedCentralCrossRef
62.
Du XJ, et al. Use of pretreatment serum uric acid level to predict metastasis in locally advanced nasopharyngeal carcinoma. Head Neck. 2017;39(3):492–7.PubMedCrossRef
63.
Yamauchi T, et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res. 2013;33(9):3947–51.PubMed
64.
Cetin AO, et al. Hyperuricemia at The Time Of Diagnosis is a Factor for Poor Prognosis in Patients With Stage II and III Colorectal Cancer (Uric Acid and Colorectal Cancer). Asian Pac J Cancer Prev. 2017;18(2):485–90.PubMedPubMedCentral
65.
Mao L, Guo C, Zheng S. Elevated urinary 8-oxo-7,8-dihydro-2’-deoxyguanosine and serum uric acid are associated with progression and are prognostic factors of colorectal cancer. Onco Targets Ther. 2018;11:5895–902.PubMedPubMedCentralCrossRef
66.
Hsueh CY, et al. Pretreatment serum uric acid as an efficient predictor of prognosis in men with laryngeal squamous cell cancer: a retrospective cohort study. Oxid Med Cell Longev. 2019;2019:1821969.PubMedPubMedCentralCrossRef
67.
Yang S, et al. Prognostic significance of serum uric acid and gamma-glutamyltransferase in patients with advanced gastric cancer. Dis Markers. 2019;2019:1415421.PubMedPubMedCentralCrossRef
68.
Dziaman T, et al. 8-Oxo-7,8-dihydroguanine and uric acid as efficient predictors of survival in colon cancer patients. Int J Cancer. 2014;134(2):376–83.PubMedCrossRef
69.
Hayashi M, et al. High serum uric acid levels could be a risk factor of hepatocellular carcinoma recurrences. Nutr Cancer. 2021;73(6):996–1003.PubMedCrossRef
70.
Stotz M, et al. Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. PLoS ONE. 2014;9(8):e104730.PubMedPubMedCentralCrossRef
71.
Wang H, et al. Correlation analysis of serum cystatin C, uric acid and lactate dehydrogenase levels before chemotherapy on the prognosis of small-cell lung cancer. Oncol Lett. 2021;21(1):73.PubMedCrossRef
72.
Xu Y, et al. Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma. BMC Cancer. 2021;21(1):519.PubMedPubMedCentralCrossRef
73.
Trindade DB, et al. Serum uric acid concentration is not associated with handgrip strength, lean body mass or survival in gastrointestinal cancer patients. Clin Nutr ESPEN. 2020;37:75–9.PubMedCrossRef
74.
75.
76.
77.
Cutler RG, et al. Uric acid enhances longevity and endurance and protects the brain against ischemia. Neurobiol Aging. 2019;75:159–68.PubMedCrossRef
78.
Prasad S, Gupta SC, Tyagi AK. Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals. Cancer Lett. 2017;387:95–105.PubMedCrossRef
79.
Li D, et al. The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications. Front Immunol. 2023;14:1282890.PubMedPubMedCentralCrossRef
80.
Chen H, et al. Can uric acid affect the immune microenvironment in bladder cancer? A single-center multi-omics study. Mol Carcinog. 2024;63(3):461–78.PubMedCrossRef
81.
Conforti-Andreoni C, et al. Uric acid-driven Th17 differentiation requires inflammasome-derived IL-1 and IL-18. J Immunol (Baltimore, Md 1950). 2011;187(11):5842–50.CrossRef
82.
Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425(6957):516–21.PubMedCrossRef
83.
Kool M, et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity. 2011;34(4):527–40.PubMedCrossRef
84.
85.
Hu D-E, et al. Uric acid promotes tumor immune rejection. Can Res. 2004;64(15):5059–62.CrossRef
86.
Shi Y, Zheng W, Rock KL. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci U S A. 2000;97(26):14590–5.PubMedPubMedCentralCrossRef
87.
Hanks BA. Immune evasion pathways and the design of dendritic cell-based cancer vaccines. Discov Med. 2016;21(114):135–42.PubMedPubMedCentral
88.
89.
Shi Y, Galusha SA, Rock KL. Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J Immunol. 2006;176(7):3905–8.PubMedCrossRef
90.
Hao S, et al. Insulin receptor substrate 1 is involved in the phycocyanin-mediated antineoplastic function of non-small cell lung cancer cells. Molecules. 2021;26(16):4711.PubMedPubMedCentralCrossRef
91.
92.
Hu Y, et al. High uric acid promotes dysfunction in pancreatic β cells by blocking IRS2/AKT signalling. Mol Cell Endocrinol. 2021;520:111070.PubMedCrossRef
93.
Yuan H, et al. Metformin ameliorates high uric acid-induced insulin resistance in skeletal muscle cells. Mol Cell Endocrinol. 2017;443:138–45.PubMedCrossRef
94.
Baldwin W, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60(4):1258–69.PubMedPubMedCentralCrossRef
95.
Liu C, et al. RBP4 is associated with insulin resistance in hyperuricemia-induced rats and patients with hyperuricemia. Front Endocrinol (Lausanne). 2021;12:653819.PubMedCrossRef
96.
He F, et al. Autophagy protects against high uric acid-induced hepatic insulin resistance. Mol Cell Endocrinol. 2022;547:111599.PubMedCrossRef
97.
Wan X, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64(4):925–32.PubMedCrossRef
98.
Jiao Z, et al. Metformin protects against insulin resistance induced by high uric acid in cardiomyocytes via AMPK signalling pathways in vitro and in vivo. J Cell Mol Med. 2021;25(14):6733–45.PubMedPubMedCentralCrossRef
99.
Choi YJ, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. Faseb j. 2014;28(7):3197–204.PubMedCrossRef
100.
Tassone EJ, et al. Uric acid impairs insulin signaling by promoting Enpp1 binding to insulin receptor in human umbilical vein endothelial cells. Front Endocrinol (Lausanne). 2018;9:98.PubMedCrossRef
101.
102.
Fathi Dizaji B. The investigations of genetic determinants of the metabolic syndrome. Diabetes Metab Syndr. 2018;12(5):783–9.PubMedCrossRef
103.
Jung SY, et al. Genetic variants and traits related to insulin-like growth factor-I and insulin resistance and their interaction with lifestyles on postmenopausal colorectal cancer risk. PLoS ONE. 2017;12(10):e0186296.PubMedPubMedCentralCrossRef
104.
Frasca F, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999;19(5):3278–88.PubMedPubMedCentralCrossRef
105.
Denley A, et al. Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol. 2004;18(10):2502–12.PubMedCrossRef
106.
107.
Sesti G, et al. Low circulating insulin-like growth factor-1 levels are associated with high serum uric acid in nondiabetic adult subjects. Nutr Metab Cardiovasc Dis. 2014;24(12):1365–72.PubMedCrossRef
108.
Fernandez ML, Upton Z, Shooter GK. Uric acid and xanthine oxidoreductase in wound healing. Curr Rheumatol Rep. 2014;16(2):396.PubMedCrossRef
109.
110.
111.
112.
113.
Li H, et al. Xanthine oxidoreductase promotes the progression of colitis-associated colorectal cancer by causing DNA damage and mediating macrophage M1 polarization. Eur J Pharmacol. 2021;906:174270.PubMedCrossRef
114.
Ullah Z, et al. A comprehensive review on recent xanthine oxidase inhibitors of dietary based bioactive substances for the treatment of hyperuricemia and gout: Molecular mechanisms and perspective. Int J Biol Macromol. 2024;278:134832.PubMedCrossRef
115.
Sun Z et al. Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents. J Med Chem. 2024.
116.
Bosly A, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer Interdiscip Int J Am Cancer Soc. 2003;98(5):1048–54.PubMedCrossRef
117.
Yang HC, et al. Gout drugs use and risk of cancer: A case-control study. Joint Bone Spine. 2018;85(6):747–53.PubMedCrossRef
118.
119.
Xue X et al. Associations between serum uric acid and breast cancer incidence: A systematic review and meta-analysis. Am J Med Sci. 2024.
120.
Huang JH, et al. Gender difference in the relationships between inflammatory markers, serum uric acid and framingham risk score. Int J Environ Res Public Health. 2021;18(13):7103.PubMedPubMedCentralCrossRef
121.
Liu H, et al. Relationship between Serum Uric Acid and Vascular Function and Structure Markers and Gender Difference in a Real-World Population of China-From Beijing Vascular Disease Patients Evaluation Study (BEST) Study. J Atheroscler Thromb. 2018;25(3):254–61.PubMedPubMedCentralCrossRef
122.
Elisabeth HA, et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69(7):1305.CrossRef
123.
Sumino H, et al. Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet. 1999;354(9179):650.PubMedCrossRef
124.
Posadzy-Małaczyńska A, et al. Effect of hormone replacement therapy on renal excretion of uric acid and prevalence of thiazide induced hyperuricemia in postmenopausal hypertensive women. Nadcisnienie Tetnicze. 2004;8(1):25–32.
125.
Budhiraja R, et al. Estrogen modulates xanthine dehydrogenase/xanthine oxidase activity by a receptor-independent mechanism. Antioxid Redox Signal. 2003;5(6):705–11.PubMedCrossRef
126.
Kurahashi H, et al. Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder. Endocr J. 2013;60(12):1321–7.PubMedCrossRef
127.
Fukai S, et al. Age-related changes in plasma androgen levels and their association with cardiovascular risk factors in male Japanese office workers. Geriatr Gerontol Int. 2010;10(1):32–9.PubMedCrossRef
128.
Usman TO, et al. Sodium acetate and androgen receptor blockade improve gestational androgen excess-induced deteriorated glucose homeostasis and antioxidant defenses in rats: roles of adenosine deaminase and xanthine oxidase activities. J Nutr Biochem. 2018;62:65–75.PubMedCrossRef
129.
Cho SK, et al. U-Shaped Association Between Serum Uric Acid Level and Risk of Mortality: A Cohort Study. Arthritis Rheumatol. 2018;70(7):1122–32.PubMedCrossRef
Metadata
Title
Linking Hyperuricemia to Cancer: Emerging Evidence on Risk and Progression
Authors
Lingyun Zhao
Ruihong Guo
Ziming Zhao
Jue Wang
Zhonghan Lou
Jianfeng Bao
Wei Zheng
Qiang Wang
Liang Qiao
Yun Ye
Hiu Yee Kwan
Hua Zhou
Qibiao Wu
Keyang Xu
Publication date
26-04-2025
Publisher
Springer US
Published in
Current Oncology Reports
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-025-01677-z

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Dr. Vivek Subbiah
Dr. Alexander Drilon
Dr. Michelle Williams
Developed by: Springer Healthcare
Watch now
Video

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
Image Credits